贝瑞基因(000710) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥367,249,676.64, a decrease of 12.78% year-on-year[7]. - Net profit attributable to shareholders was ¥33,360,093.21, down 47.68% compared to the same period last year[7]. - The company reported a net profit of ¥150,831,923.37 for the year-to-date, a decrease of 51.87% compared to the same period last year[7]. - Basic earnings per share were ¥0.0941, a decrease of 47.66% year-on-year[7]. - The company reported a net profit margin decline, with undistributed profits at CNY 1,017,491,330.25 compared to CNY 866,659,406.87 in the previous period[35]. - The net profit for the third quarter of 2020 was CNY 146,827,353.17, a decrease of 52.7% compared to CNY 310,545,632.88 in the same period last year[49]. - The total profit for the third quarter was CNY 185,096,532.36, down from CNY 360,700,576.93, reflecting a decline of 48.7% year-over-year[49]. - The company reported a comprehensive income total of CNY 32,339,024.42 for the quarter, reflecting a decrease of 48.54% compared to CNY 62,899,802.09 in the previous year[43]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,221,700,435.41, an increase of 4.98% compared to the end of the previous year[7]. - Current liabilities rose to CNY 551,915,642.36, up from CNY 449,718,880.72, indicating an increase of approximately 23%[34]. - Non-current liabilities increased to CNY 329,687,437.50 from CNY 272,111,362.93, marking a rise of around 21%[34]. - Total liabilities reached CNY 721,830,243.65, with current liabilities at CNY 449,718,880.72 and non-current liabilities at CNY 272,111,362.93[65]. - Owner's equity totaled CNY 2,347,046,643.19, including share capital of CNY 354,605,865.00 and retained earnings of CNY 866,659,406.87[65]. Cash Flow - The net cash flow from operating activities was ¥76,004,633.30, an increase of 36.52% compared to the previous year[7]. - The net cash flow from operating activities was -34,706,084.02 CNY, a decrease from 87,352,689.69 CNY in the previous period[56]. - Total cash inflow from operating activities was 987,780,042.70 CNY, compared to 1,106,323,154.00 CNY in the same period last year, indicating a decline of approximately 10.7%[56]. - Cash outflow from operating activities totaled 1,022,486,126.72 CNY, slightly increased from 1,018,970,464.31 CNY[56]. - The net cash flow from investing activities was -69,788,961.38 CNY, compared to -320,555,611.94 CNY in the previous period, showing an improvement[57]. - Cash inflow from financing activities was 380,845,754.88 CNY, up from 176,760,105.60 CNY in the previous period, representing a significant increase of approximately 115.5%[57]. Shareholder Information - The total number of shareholders at the end of the reporting period was 18,739[11]. - The largest shareholder, Gao Yang, holds 13.89% of the shares, amounting to 49,260,572 shares, with a portion pledged[11]. Investments and Expenses - Research and development expenses increased to CNY 33,230,928.07, up 14.83% from CNY 29,009,576.30 year-over-year[41]. - Financial expenses increased by 8054.65% to RMB 9,442,539.82, primarily due to increased loan interest expenses[15]. - The company has ongoing investments in fixed assets totaling CNY 506,778,116.04, down from CNY 541,996,643.13, reflecting a decrease of approximately 6%[33]. - The company recorded a net loss from joint ventures and associates of CNY 28,239,541.49, worsening from a loss of CNY 42,374,451.19 in the previous year[49]. Other Key Information - Non-recurring gains and losses totaled ¥34,693,319.08, primarily from the disposal of non-current assets and government subsidies[8]. - The company plans to implement an employee stock ownership plan with a capital scale not exceeding RMB 39 million, involving the repurchase of 3,900,000 shares[17]. - The company expects to engage in related transactions with Fujian He Rui for tumor-related products and services, estimating a total transaction amount of RMB 10 million[17]. - The company has no overdue commitments from major shareholders or related parties during the reporting period, indicating stable governance[20]. - The third quarter report has not been audited[71].